IRVINE, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced the launch of two new purpose-built products, the RevCore thrombectomy catheter, and the Triever16 Curve catheter.
Nearly half a million venous stents have been placed in the US in the past decade. RevCore is the first mechanical thrombectomy device designed to address venous in-stent thrombosis, an increasingly common occurrence impacting more patients every year. The device includes a unique diameter-controlled coring element specifically designed to safely engage thrombus within stents. With RevCore, Inari has developed a solution for an entirely new patient population not currently addressed by the ClotTriever or FlowTriever platforms. Inari will be co-hosting a Webinar with the Venous Symposium today, Wednesday June 7th at 7pm ET (4pm PT) to introduce RevCore and review the initial case experience. Register here.
“Until now, physicians have had limited options to treat patients suffering from symptoms of venous stent failure and some patients are relegated to repeated suboptimal interventions,” said Dr. Steven Abramowitz, Chair of Vascular Surgery at MedStar Health in Washington, DC. “RevCore is a game changer as it physically removes in-stent thrombus, restores flow, and could potentially reduce the need for additional reintervention. There are a lot of patients out there that may benefit from the RevCore procedure.”
The Triever16 Curve catheter, the latest addition to the FlowTriever platform, is purpose-built to be versatile for both pulmonary embolism and peripheral thrombectomy. The highly trackable catheter features a pre-shaped curve for targeted aspiration. Triever16 Curve offers unique advantages over 16F continuous aspiration catheters, including compatibility with FlowSaver blood return system and simple access to larger, more powerful 20F or 24F catheters within Inari’s price-per-procedure model.
“Triever16 Curve is an important addition to the already comprehensive Inari VTE toolkit,” said Dr. Angelo Marino, Interventional Radiologist and Assistant Professor of Clinical Radiology and Biomedical Imaging at Yale School of Medicine. “Every VTE patient is different. With both aspiration and mechanical bloodless thrombectomy options available, including multiple sizes and shapes of large-bore aspiration catheters, we are equipped to treat nearly every VTE patient that comes in the door.”
“We are thrilled to announce the commercial launch of these two products, which reinforce our unwavering commitment to addressing unmet needs with purpose-driven innovation,” said Drew Hykes, Inari’s Chief Executive Officer. “We continue to push the boundaries, and we are excited about the potential impact we can make on patients' lives with these products and beyond.”
About Inari Medical, Inc.
Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underrecognized health needs. In addition to our purpose-built products, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous thromboembolism and beyond. We are just getting started.
Investor Contact:
Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$49.00 |
Daily Change: | -1.97 -3.87 |
Daily Volume: | 631,517 |
Market Cap: | US$2.860B |
October 29, 2024 October 28, 2024 August 29, 2024 August 21, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB